May 2 |
Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic Advancements
|
May 1 |
Neurocrine Q1 revenue beats Street, gets FDA okay for Ingrezza Sprinkle
|
May 1 |
Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript
|
May 1 |
Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech
|
May 1 |
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
|
May 1 |
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
|
May 1 |
Neurocrine Biosciences Non-GAAP EPS of $1.20 misses by $0.09, revenue of $515.3M beats by $3.29M
|
May 1 |
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
|
Apr 30 |
UPDATE 2-Neurocrine Biosciences' Huntington's disease drug gets FDA approval
|
Apr 30 |
Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
|